With advances in genomic sequencing technology, the number of reported gene-disease
relationships has rapidly expanded. However, the evidence supporting these claims varies …

Background: Genetic testing for families with hypertrophic cardiomyopathy (HCM) provides
a significant opportunity to improve care. Recent trends to increase gene panel sizes often …

The rapid development of genomic sequencing technologies has decreased the cost of
genetic analysis to the extent that it seems plausible that genomescale sequencing could have …

Genome‐scale sequencing creates vast amounts of genomic data, increasing the challenge
of clinical sequence variant interpretation. The demand for high‐quality interpretation …

As whole exome sequencing (WES) becomes more widely used in the clinical realm, a
wealth of unanalyzed information will be routinely generated. Using WES read depth data to …

Newborn screening (NBS) was established as a public health program in the 1960s and is
crucial for facilitating detection of certain medical conditions in which early intervention can …

Objective To assess the performance of a standardized, age-based metric for scoring clinical
actionability to evaluate conditions for inclusion in newborn screening and compare it with …

Objective To evaluate the diagnostic yield and workflow of genome-scale sequencing in
patients with neuromuscular disorders (NMDs). Methods We performed exome sequencing in …

Background Newborn screening aims to identify individual patients who could benefit from
early management, treatment, and/or surveillance practices. As sequencing technologies …

Studies suggest that 1–3% of the general population in the United States unknowingly carry
a genetic risk factor for a common hereditary disease. Population genetic screening is the …